Brain Biotech (BNN.DE) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

BNN.DE · Stock Price

EUR 3.25+1.19 (+57.77%)

Market Cap: $81.3M

Historical price data

Overview

BRAIN Biotech AG is a publicly traded German leader in industrial biotechnology, founded in 1993. It operates as a service-driven innovation partner, providing contract R&D and tailored biosolutions to industrial clients. Its strategy centers on a modular technology platform encompassing enzyme engineering, a proprietary methanol-free protein expression system, and advanced bioprocess development. The company aims to enable a bio-based future by solving complex scientific challenges for its partners, thereby generating service revenue without developing its own proprietary therapeutics.

Technology Platform

Integrated platform combining proprietary enzyme discovery (MetXtra™), microbial strain engineering (methanol-free Komagataella phaffii system, CRISPR-BMC), and bioprocess development to create tailored industrial biosolutions.

Pipeline

200

200 drugs in pipeline21 in Phase 3

Drug	Indication	Stage
Celecoxib 400mg + Placebo	Depressive Disorder, Major	Phase 3
citicoline + L-Alpha glycerylphosphorylcholine + cerebrolysi...	Stroke	Phase 3
Inhaled isoflurane administered by Sedaconda ACD-S + Intrave...	Post-Intensive Care Syndrome	Phase 3
indomethacin	Alzheimer Disease	Phase 3
Minocycline 100mg	Multiple Sclerosis	Phase 3

Funding History

2

Total raised:$17.5M

Grant$2.5MGerman Federal Ministry of Education and ResearchMay 15, 2021

IPO$15MUndisclosedSep 15, 2016

Opportunities

The global shift towards sustainable, bio-based production in chemicals, food, and agriculture creates a vast and growing addressable market.

BRAIN's proprietary methanol-free protein expression system and CRISPR-BMC editing tools position it as a key enabler for companies developing next-generation bioproducts, from alternative proteins to biodegradable materials.

Risk Factors

Revenue is project-based and can be volatile, dependent on a limited number of client decisions.

Intense competition from larger industrial biotech firms and the risk of technical failures during complex bioprocess scale-up pose significant challenges to growth and profitability.

Competitive Landscape

Competes against large enzyme producers (e.g., Novozymes/Chr. Hansen), broad CDMOs, and niche R&D boutiques. BRAIN differentiates through its integrated discovery-to-scale-up service model and ownership of proprietary platforms like its methanol-free Komagataella phaffii expression system.

More companies in Synthetic Biology →More companies in Germany →